Adolescents and young adults with type 1 diabetes (T1D) are at high risk for developing early cardiovascular disease \[[@B1]\]. Current recommendations to consider pharmacologic treatment of elevated low-density lipoprotein cholesterol (LDL-c) are based on limited evidence and extrapolation from data in middle age and older adults. We proposed a trial of lipid-lowering medications (simvastatin, a statin, compared to Vytorin, a combination of simvastatin and ezetimibe, a medication that blocks cholesterol absorption) in our patients ages 12--21 years with LDL ≥ 130 mg/dl, consistent with current American Diabetes Association (ADA) guidelines. In this study, we hypothesized that simvastatin and Vytorin would be safe in adolescents with T1D and that in a two-arm design, Vytorin would lower LDL-c more than monotherapy with simvastatin at 6 months compared to baseline. In this report, we describe observations from a trial of lipid-lowering medications in T1D, age 12--21 years.

In 2004 we ascertained that the Barbara Davis Center for Childhood Diabetes (BDC) followed 1,528 patients with T1D age 12--21 years. The SEARCH for Diabetes in Youth study reported LDL-c \>130 mg/dl in 15% of T1D subjects \[[@B2]\]. Based on these data, we estimated that 229 T1D patients age 12--21 years seen at the BDC would have LDL-c \>130 mg/dl. A randomized, double-blind, placebo-controlled study of lipid-lowering medications required 82 enrolled subjects which assumed a 36% participation rate. Inclusion criteria were age 12--21 years with T1D diagnosed by positive islet autoantibodies or provider diagnosis of T1D, and LDL-c \> 130 mg/dl. Patients with familial hypercholesterolemia, triglycerides \> 400 mg/dl, T1D of less than three-months duration, HbA1c \> 9.5%, abnormal thyroid function, abnormal creatine kinase values, abnormal liver function tests (ALT/AST), pregnancy or potential to become pregnant during the study, and patients on oral contraceptives were excluded.

Findings
========

We identified 105 potential subjects with clinically measured LDL-c \>130 mg/dl or non-HDL-c \>160 mg/dl. Of these, 42 patients proved to be ineligible (A1c \> 9.5%, LDL-c \< 130 mg/dl on a repeat test), 26 declined invitation to a screening visit, 16 expressed one time interest but were not able to be scheduled, and 3 were interested but were unable to improve their glycemic control to be eligible for the study. Therefore, 18 agreed to be in the study and 17 subjects attended a study screening visit of which 9 were enrolled in the study (15.8 ± 2.8 years, 67% male, A1c = 8.3 ± 1.1%, TC = 224 ± 42, HDL-c = 51 ± 11, TG = 112 ± 66, LDL-c = 151 ± 29 mg/dl, BMI = 25.4 ± 5.0 kg/m^2^) (Figure [1](#F1){ref-type="fig"}). Reasons for poor recruitment included elevated A1c (\>9.5%), improved LDL-c from clinic lipid panels to screening visit (n = 42, 40%), lack of interest in taking a lipid-lowering medication and/or long distance to travel to study site (n = 21, 20%). A positive result of our study was improved compliance with lipid screening in our clinic population (a 55% reduction, from 416 to 188) in subjects eligible for, but lacking screening lipids over 2.5 years.
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Despite current recommendations for intensified glycemic control, diet, and exercise as initial therapies for dyslipidemia, some adolescents with T1D will not reach the LDL-c goal of \<100 mg/dl. For these patients, data are needed on the safety, efficacy, and ultimately the risk/benefit of dyslipidemia medications initiated in adolescence. We are aware of only one published short-term clinical trial of dyslipidemia medication in adolescents with T1D \[[@B3]\], although a Juvenile Diabetes Research Foundation sponsored trial is on-going in the United Kingdom \[[@B4]\]. Increased awareness of lipid health and treatment options in this patient population are needed as some patients and families required months of deliberation before deciding to have the patient take a dyslipidemia medication in addition to intensification of glycemic control, diet, and exercise. Based on our experience, future studies will require multiple centers to enroll a sufficient number of participants for adequate data to direct treatment guidelines for pharmacologic treatment of dyslipidemia in adolescents with T1D.
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